These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39029547)

  • 21. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes.
    Lai J; Syngelaki A; Nicolaides KH; von Dadelszen P; Magee LA
    Am J Obstet Gynecol; 2021 May; 224(5):518.e1-518.e11. PubMed ID: 33166504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maternal serum soluble fms-like tyrosine kinase-1-to-placental growth factor ratio distinguishes growth-restricted from non-growth-restricted small-for-gestational-age fetuses.
    Rajiv P; Cade T; Dean J; Jones GD; Brennecke SP
    AJOG Glob Rep; 2024 Feb; 4(1):100302. PubMed ID: 38318268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood.
    Chaiworapongsa T; Romero R; Gotsch F; Suksai M; Gallo DM; Jung E; Krieger A; Chaemsaithong P; Erez O; Tarca AL
    Am J Obstet Gynecol; 2023 May; 228(5):569.e1-569.e24. PubMed ID: 36336082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).
    Chaiworapongsa T; Romero R; Erez O; Tarca AL; Conde-Agudelo A; Chaemsaithong P; Kim CJ; Kim YM; Kim JS; Yoon BH; Hassan SS; Yeo L; Korzeniewski SJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):682.e1-682.e13. PubMed ID: 29037482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio.
    Villalaín C; Herraiz I; Valle L; Mendoza M; Delgado JL; Vázquez-Fernández M; Martínez-Uriarte J; Melchor Í; Caamiña S; Fernández-Oliva A; Villar OP; Galindo A
    J Am Heart Assoc; 2020 Apr; 9(7):e015548. PubMed ID: 32248765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum amyloid A1 and pregnancy zone protein in pregnancy complications and correlation with markers of placental dysfunction.
    Fosheim IK; Jacobsen DP; Sugulle M; Alnaes-Katjavivi P; Fjeldstad HES; Ueland T; Lekva T; Staff AC
    Am J Obstet Gynecol MFM; 2023 Jan; 5(1):100794. PubMed ID: 36334725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of the soluble fms-like tyrosine kinase 1 to placental growth factor ratio for preeclampsia in twin pregnancies: a systematic review and meta-analysis.
    Yang M; Bai Y; Li M; Lin X; Duan X; Zhang X
    Am J Obstet Gynecol MFM; 2024 Mar; 6(3):101290. PubMed ID: 38401234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy.
    Palomo M; Youssef L; Ramos A; Torramade-Moix S; Moreno-Castaño AB; Martinez-Sanchez J; Bonastre L; Pino M; Gomez-Ramirez P; Martin L; Garcia Mateos E; Sanchez P; Fernandez S; Crovetto F; Escolar G; Carreras E; Castro P; Gratacos E; Crispi F; Diaz-Ricart M
    Am J Obstet Gynecol; 2022 Aug; 227(2):277.e1-277.e16. PubMed ID: 35351411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A longitudinal analysis of angiotensin II type 1 receptor antibody and angiogenic markers in pregnancy.
    Aggarwal S; Sunderland N; Thornton C; Xu B; Hennessy A; Makris A
    Am J Obstet Gynecol; 2017 Feb; 216(2):170.e1-170.e8. PubMed ID: 27793555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Midgestation maternal serum 25-hydroxyvitamin D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio as predictors of severe preeclampsia.
    Woodham PC; Brittain JE; Baker AM; Long DL; Haeri S; Camargo CA; Boggess KA; Stuebe AM
    Hypertension; 2011 Dec; 58(6):1120-5. PubMed ID: 21986503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio.
    Buhimschi CS; Baumbusch MA; Dulay AT; Lee S; Wehrum M; Zhao G; Bahtiyar MO; Pettker CM; Ali UA; Funai EF; Buhimschi IA
    BJOG; 2010 Feb; 117(3):321-30. PubMed ID: 19943826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiogenic and vasoactive proteins in the maternal-fetal interface in healthy pregnancies and preeclampsia.
    Westerberg AC; Degnes ML; Andresen IJ; Roland MCP; Michelsen TM
    Am J Obstet Gynecol; 2024 Nov; 231(5):550.e1-550.e22. PubMed ID: 38494070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Confirmation of preeclampsia-like syndrome induced by severe COVID-19: an observational study.
    Serrano B; Bonacina E; Garcia-Ruiz I; Mendoza M; Garcia-Manau P; Garcia-Aguilar P; Gil J; Armengol-Alsina M; Fernández-Hidalgo N; Sulleiro E; Castillo-Ribelles L; Maiz N; Carreras E; Suy A
    Am J Obstet Gynecol MFM; 2023 Jan; 5(1):100760. PubMed ID: 36195282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating angiogenic proteins in trisomy 13.
    Bdolah Y; Palomaki GE; Yaron Y; Bdolah-Abram T; Goldman M; Levine RJ; Sachs BP; Haddow JE; Karumanchi SA
    Am J Obstet Gynecol; 2006 Jan; 194(1):239-45. PubMed ID: 16389038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study.
    Dröge LA; Perschel FH; Stütz N; Gafron A; Frank L; Busjahn A; Henrich W; Verlohren S
    Hypertension; 2021 Feb; 77(2):461-471. PubMed ID: 33280406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes.
    Coolman M; Timmermans S; de Groot CJ; Russcher H; Lindemans J; Hofman A; Geurts-Moespot AJ; Sweep FC; Jaddoe VV; Steegers EA
    Obstet Gynecol; 2012 Jun; 119(6):1190-200. PubMed ID: 22617584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Soluble fms-Like Tyrosine Kinase 1/Placental Growth Factor Ratio Alone versus a Multi-Marker Regression Model for the Prediction of Preeclampsia-Related Adverse Outcomes after 34 Weeks of Gestation.
    Sroka D; Lorenz-Meyer LA; Scherfeld V; Thoma J; Busjahn A; Henrich W; Verlohren S
    Fetal Diagn Ther; 2023; 50(3):215-224. PubMed ID: 36809755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
    Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
    PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array.
    Yagel S; Cohen SM; Goldman-Wohl D
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S963-S972. PubMed ID: 33712272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.